Despite current treatment regimens with curative intent, including surgery, radiotherapy and chemotherapy, local or distant recurrence rates remain high, and the 5‐year overall survival rate of HNSCC patients is less than 50%.33 Emerging therapeutic strategies, such as anti‐EGFR antibody (cetuximab) and anti‐PD‐1 antibodies (pembrolizumab and nivolumab) that have recently been approved for the treatment of advanced and metastatic HNSCC, are promising options for the management of high‐risk patients. Here, EGFR is linked to head and neck squamous cell carcinoma.